LncRNA HOXA-AS2 and its molecular mechanisms in human cancer

Long non-coding RNAs (lncRNAs), a novel class of noncoding RNAs, are commonly defined as RNA molecules more than 200 nucleotides in length. Emerging research indicated that lncRNA played a vital role in human tumorigenesis and progression by serving as tumor oncogenes or suppressors. LncRNA has been...

Full description

Saved in:
Bibliographic Details
Published in:Clinica chimica acta 2018-10, Vol.485, p.229-233
Main Authors: Wang, Jicai, Su, Zhilei, Lu, Shounan, Fu, Wen, Liu, Zhifa, Jiang, Xingming, Tai, Sheng
Format: Article
Language:English
Subjects:
Diagnosis
HOXA-AS2
lncRNA
Prognosis
Therapeutic target
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Long non-coding RNAs (lncRNAs), a novel class of noncoding RNAs, are commonly defined as RNA molecules more than 200 nucleotides in length. Emerging research indicated that lncRNA played a vital role in human tumorigenesis and progression by serving as tumor oncogenes or suppressors. LncRNA has been shown to get involved in participate various biological processes, such as cell growth, anti-apoptosis, migration and invasion. LncRNA HOXA cluster antisense RNA2 (HOXA-AS2) is a novel cancer-related lncRNA. It was recently found to exhibit aberrant expression in a variety of malignancies, including breast cancer, gastric cancer, gallbladder carcinoma, hepatocellular carcinoma and pancreatic cancer. The oncogenicity of lncRNA HOXA-AS2 mainly inhibits or promotes the expression of related genes through direct or indirect pathways, suggesting that HOXA-AS2 likely represents a feasible biomarker or therapeutic target in human cancers. In this review, we summarize current evidences concerning the biological functions and mechanisms of HOXA-AS2 during tumor development. •• The different regulatory mechanisms of lncRNA HOXA-AS2 in tumors•• The relationship between high HOXA-AS2 expression and clinicopathologic characteristics of cancer patients•• HOXA-AS2 could be a novel prognostic biomarker for cancer patients.
ISSN:0009-8981
1873-3492
DOI:10.1016/j.cca.2018.07.004